


PRODUCT: Ezutromid**ALTERNATE NAME:** 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole; BMN-195**CATALOG #:** B1248-5,25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₁₉H₁₅NO₃S**MOLECULAR WEIGHT:** 337.39**CAS NUMBER:** 945531-77-1**APPEARANCE:** Light brown solid**SOLUBILITY:** DMSO (> 10 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20°C. Protect from air and light.**DESCRIPTION:** Ezutromid is a first orally available drug for the treatment of Duchenne muscular dystrophy (DMD), a lethal, X-linked muscle wasting disease caused due to lack of dystrophin-a cytoskeleton protein. Ezutromid has shown potential as disease modifying treatment for DMD patients irrespective of their gene mutation. Ezutromid acts on utrophin modulation and has potential to slow down or stop the progression of DMD.**REFERENCES:** Guiraud, S., *et.al.* (2015). *Hum. Mol. Genet.* **24**, 4212-4224**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**Dystrophin antibody (**3586R**)Dystrophin blocking peptide (**3586RBP-50**)**USAGE:** **FOR RESEARCH CH USE ONLY! Not to be used in humans**